Cyclopharm Limited · ASX:CYC
Cyclopharm — Shareholder Meeting (May 2021)
37 slides from Cyclopharm's shareholder meeting presentation, May 4, 2021
Slide 1: Cyclopharm 2021 Annual General Meeting
CYCLOPHARM 2021 Annual General Meeting 4 May 2021 1
Slide 2: Safe Harbour Statement
Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of Cyclopharm Limited and as to the
Slide 3: Welcome
Welcome Mr David Heaney 3
Slide 4: Chairman's Address
CHAIRMAN’S ADDRESS Mr David Heaney 4
Slide 5: Technegas Around the World
TECHNEGAS® AROUND THE WORLD Technegas® was introduced to the medical community in 1986 Technegas® revenues are generated in over 60 countries via a combination of direct and distributor sales models HQ Over 4.3 million patient procedures Available Seeking Approval CYC subsidiaries to date 5
Slide 6: Managing Director's Address
MANAGING DIRECTOR’S ADDRESS Mr James McBrayer 6
Slide 7: Financial Highlights
Sales Revenue Record Group Sales revenue of $14.7m, up 4.2% Third Party Distribution $2.2 million of new third‐party distribution revenue 2020 Net Loss Before Tax $5.8 million loss (includes $3.9m from USFDA expenses + Forex on refunded FDA fees) Financial R&D Tax Incentive $3.0 million received in
Slide 8: Operating Highlights
Covid Recovery Technegas™ sales rebound by 51.4% in 2H after pandemic impacted first half USFDA Phase 3 trials confirmed to meet Primary and 2020 Secondary Efficacy Endpoints in Sept 2020 US Commercialisation Investing to build inventory reserves; distribution, Operating service and installation out
Slide 9: Building for Growth
BUILDING FOR GROWTH Technegas® is a substantially de-risked commercial proposition with significant upside in the USA market • Total global sales of over $80m AUD from 2015 to 2020 • Technegas® currently available in over 60 countries • Over 4,300,000 patient procedures performed since first approve
Slide 10: Coming to America in 2021
COMING TO AMERICA IN 2021 10
Slide 11: Immediate Market Opportunity
600K Nuclear Medicine Ventilation 15%/600k Procedures p.a. • 4,000,000 patient procedures conducted in the USA per annum to diagnose pulmonary embolism (15% Nuclear Medicine – 85% CTPA) • 600,000 Nuclear Medicine Ventilation procedures equals $90m USD • Target market for Technegas® in the USA equate
Slide 12: USA Commercialisation Pathway
Clinical Regulatory ➢ Key Opinion Leaders engaged ➢ Pre-approval audit complete ➢ Recruit Chief Medical Officer. ➢ Labelling requirements - May 2021 ➢ R&D Programs Beyond PE Underway ➢ Completion Goal Date - 26 June 2021 Commercial 3PL ➢ Recruit BDM ➢ Short-list distribution providers identified USA
Slide 13: USA Pricing & Business Model
USA Pricing & Business Model Generators are to be placed at no cost removing potential 1 CAPEX roadblocks 2 Once off installation and training fee charged 3 Ongoing annual fee attributed to preventative maintenance, training and product support Business model expected to result in accelerated Consum
Slide 14: USA Demand Established
USA Demand Established No requirement for large sales team due to pre-approval demand 1 9 sites in the US already have generators installed from clinical trials Multiple letters from leading clinicians and front-line workers petitioning the USFDA to expedite approval of Technegas™. 2 The most recent
Slide 15: The Canadian Case Study
TECHNEGAS® The Canadian Case Study Canada is Cyclopharm’s largest single country market The Generator and Consumable Relationship 1 Market leader for diagnosing PE Technegas® Growth - Canada 50 160 2 14 consecutive years of pre-Covid19 procedure growth 45 140 40 3 Represents a strong indicator of US
Slide 16: Expanding Indications
n AN U =—C&RAN EXPANDING INDICATIONS +
Slide 17: Building from Strong Foundations
Building from Strong Foundations! “ Using 99m-Tc-Technegas is according to clinical experience better than the best aerosols ” “ Technegas® facilitates interpretation, particularly in COPD” “ For ventilation, 99m-Tc Technegas® is the best-aerosol particularly in patients with COPD ” “ Liquid aerosol
Slide 18: Beyond PE applications of V/Q SPECT(/CT)
Beyond PE applications of V/Q SPECT(/CT) Diagnosis and Preoperative Preoperative Planning radiation Advanced approach to Diagnosis and follow-up of assessment of assessment of therapy to target phenotyping chronic monitoring of COVID- Pulmonary homogeneous lung resection tumors while airways disease
Slide 19: Technegas literature beyond PE
TECHNEGAS® 66% of references citing Technegas® in the past 24 months In recent literature are for indications Beyond PE 1. King GG, et al. Dismantling the pathophysiology of asthma using imaging. Eur Respir Rev 2019; 28(152): 16. Dimastromatteo J, et al. Molecular imaging of pulmonary diseases. Resp
Slide 20: Beyond PE: Clinical Initiatives
BEYOND PE : Clinical Initiatives Clinical Trials Sponsored by Cyclomedica • Hunter Medical Research Institute (Newcastle, AU): Diagnosis and response to therapy in severe asthma and COPD1 PATIENT MANAGEMENT • Woolcock Institute (Sydney, AU): & SCREENING Diagnosis and response therapy in mild to mode
Slide 21: Three Revenue Horizons
THREE REVENUE HORIZONS Horizon 2 3 to 8 Years Horizon 3 Convert CTPA >8 Years Horizon 1 $USD POTENTIAL Double existing Nuc Med Innovate Beyond PE 0 to 5 Years Procedures for PE HALF BILLION Establish USA combined sufferers of Asthma 80% Conversion of Nuc Med and Chronic Obstructive Procedures for PE
Slide 22: Key Catalysts for the Next 2 Years
KEY Catalysts for the Next 2 Years 1 FDA approval for Technegas expected mid 2021 2 First sales in US announce (shortly after approval) 3 Ongoing updates on No. Generators placed in US Additional guidelines and clinical papers to come out on the use of 4 Technegas in both pulmonary embolism and addi
Slide 23: Cyclopharm Investment Case
CYCLOPHARM INVESTMENT CASE Profitable and First in Class Recurring Revenue USFDA Approval Optionality Growing MedTech Established Gold Standard From single patient Set to quadruple the size Into indications beyond PE Underlying business Proprietary product sales to consumables of the existing PE bus
Slide 24: Business Q&A
Business Q&A 24
Slide 25: Formal Business
FORMAL BUSINESS Mr David Heaney 25
Slide 26: 2021 AGM – Formal Business
2021 AGM – Formal Business (a) Financial Statements !1 (b) Remuneration Report !2 Re-election of Director – Mr Tom McDonald !3 Ratification of the Prior Issue of Placement Shares !4 Approval of Loan Share Plan !5 Amendment of Constitution !6 Approval of Non-executive Director Remuneration 26
Slide 27: Online Attendees – Registration Process & Voting
Online Attendees – Registration Process & Voting 1 2 3 Go to Once logged in you will see that Click on “register” to register https://investor.automic.com.au/ the meeting is open for your attendance for the meeting #/home registration. Click on “view”
Slide 28: Online Attendees – Question Process & Voting
Online Attendees – Registration Process Question Process & Voting & Voting TBC 4 5 6 Once the Chair of the Meeting To vote simply select the Once voting is declared closed declares voting open, you direction in which you would like you must select “next” and then should select “refresh” to cast your
Slide 29: CYC AGM 2021 Resolutions: Remuneration Report
CYC AGM 2021 Resolutions 1 That the Remuneration Report as set out in the Annual Report of the Company for the financial year ended 31 December 2020 be adopted. Resolution For Against Discretionary Abstain 1(b) Remuneration Report 27,808,324 67,474 29,050,049 261,846 Questions? 29
Slide 30: CYC AGM 2021 Resolutions: Re-election of Director
CYC AGM 2021 Resolutions 2 That, for the purposes of ASX Listing Rule 14.5 and for all other purposes, Mr Tom McDonald, who retires at the close of this Annual General Meeting and, being eligible, and having consented to act, be re-elected as a Director of the Company. Resolution For Against Discret
Slide 31: CYC AGM 2021 Resolutions: Ratification of Placement Shares
CYC AGM 2021 Resolutions 3 That for the purposes of ASX Listing Rule 7.4 and for all other purposes, shareholders ratify the issue of 11,538,462 fully paid ordinary shares at an issue price of $2.60 per share, issued by way of a placement to sophisticated and institutional investors on 27 January 20
Slide 32: CYC AGM 2021 Resolutions: Loan Share Plan
CYC AGM 2021 Resolutions 4 That the Cyclopharm Loan Share Plan, a summary of which is set out in the Explanatory Statement, be approved for the purposes of ASX Listing Rule 7.2 (Exception 13), sections 200E, 259B(2) and 260C(4) of the Corporations Act and for all other purposes. Resolution For Again
Slide 33: CYC AGM 2021 Resolutions: Amendment of Constitution
CYC AGM 2021 Resolutions 5 That the current constitution of the Company be amended, effective from the close of the AGM, as set out in the document tabled at the 2021 Annual General Meeting and signed by the chairperson for the purposes of identification. Resolution For Against Discretionary Abstain
Slide 34: CYC AGM 2021 Resolutions: Non-executive Director Remuneration
CYC AGM 2021 Resolutions 6 That for the purposes of Listing Rule 10.17 and for all other purposes, the shareholders of the Company approve the increase of the maximum aggregate amount payable to non-executive directors by way of directors' fees from $250,000 to $350,000. Resolution For Against Discr
Slide 35: 2021 AGM – Proxy Summary
2021 AGM – Proxy Summary Resolution For Against Discretionary Abstain 1(b) Remuneration Report 27,808,324 67,474 29,050,049 261,846 2 Re-election of Director 30,435,886 35,099 29,062,537 14,833 3 Ratification of the Prior Issue 16,431,535 35,099 29,050,049 14,089,264 of Placement Shares 4 Approval o
Slide 36: Technegas: Votes are Being Tabulated
Technegas: World’s Best Functional Lung Ventilation Imaging Agent Votes are Being Tabulated 36
Slide 37: Thank You
T H A N K YO U 37